Inovio (Nasdaq:INO) announced today that it appointed Dr. Michael Sumner as its new chief medical officer (CMO). Sumner will oversee Inovio’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, along with regulatory affairs, pharmacovigilance and medical affairs. He will also serve on the company’s executive leadership team and report to President […]
Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast. INO shares were down more than –11% at $8.53 per share in morning trading today. Get the full story at our sister site, Drug Delivery Business News.
Inovio Pharmaceuticals (NSDQ:INO) shares dipped after hours today after the company presented its fourth-quarter earnings and touted clinical trial results. INO shares finished the day up 4.5% at $11.60 per share but have since dropped -2.2% after hours to $11.35 per share. The Plymouth Meeting, Pa.-based company posted losses of -$24.3 million, or -14¢ per share, […]
The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
A week after topping pre-pandemic highs, the medtech industry’s stocks were brought back down to earth in quick fashion. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 89.03 (Sep. 11), marking a -0.3% dip from the 89.29 points registered at the end of the […]
Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by 2021, […]
Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver its INO-4800 COVID-19 vaccine candidate directly into the skin. […]
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. Get the full […]
Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 million in notes. Get the full story at our sister site, Drug Delivery Business News.
Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial. The company found that Pennvax-GP plasmids delivered intradermally with Inovio’s Cellectra device triggered equivalent or superior immune responses in healthy volunteers compared to intramuscular delivery of the plasmids using the same device. […]
Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection. The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained […]